Coagulation factor ix and / or activated coagulation factor ix as well as methods of using bispecific antibodies recognizing coagulation factor x and / or activated coagulation factor x

A bispecific antibody dosing regimen for hemophilia A addresses the limitations of current treatments by offering a less frequent, subcutaneous option that effectively reduces bleeding episodes through sustained FVIII activity.

JP2024161483AInactive Publication Date: 2024-11-19CHUGAI PHARMA CO LTD +1

Patent Information

Application Number
JP2024135511
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-04-14
Filing Date
2024-08-15
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for hemophilia A, such as FVIII preparations and bypass agents, are burdensome, require frequent administration, and may not be effective for patients with inhibitors, necessitating a less frequent, subcutaneous, and long-acting therapeutic option.

Method used

A dosing regimen involving bispecific antibodies that recognize FIX and/or FIXa and FX and/or FXa, administered with a loading dose followed by maintenance doses at specific intervals to replace the function of FVIII, including weekly, biweekly, and monthly schedules.

Benefits of technology

The regimen effectively reduces bleeding episodes in hemophilia A patients, including those with inhibitors, by providing sustained therapeutic levels of FVIII activity with improved patient convenience and compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161483000009
    Figure 2024161483000009
  • Figure 2024161483000010
    Figure 2024161483000010
  • Figure 2024161483000011
    Figure 2024161483000011
Patent Text Reader

Abstract

To provide effective pharmaceutical compositions or dosing regimens for the prevention and / or treatment of bleeding, disorders associated with bleeding, or disorders caused by bleeding.SOLUTION: We found out that administering a pharmaceutical composition containing a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX, and (b) blood coagulation factor X and / or activated blood coagulation factor X, according to a predetermined dosing regimen can prevent and / or treat bleeding, diseases associated with bleeding, or diseases caused by bleeding more effectively.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 383,933, filed September 6, 2016, U.S. Provisional Application No. 62 / 437,281, filed December 21, 2016, and U.S. Provisional Application No. 62 / 485,514, filed April 14, 2017, the disclosures of which are incorporated herein by reference in their entireties.

[0002] The present invention relates generally to the field of therapeutic agents for bleeding disorders. [Background technology]

[0003] Hemophilia is a bleeding disorder caused by congenital deficiency or dysfunction of coagulation factor VIII (FVIII) or coagulation factor IX (FIX). The former is called hemophilia A, and the latter is called hemophilia B. The genes for both factors are located on the X chromosome, and the genetic abnormality is an X-linked recessive inheritance pattern, so that more than 99% of patients who develop the disease are male. The prevalence is known to be approximately 1 per 10,000 male births, and the ratio of hemophilia A to hemophilia B is approximately 5:1.

[0004] The severity of hemophilia A is defined by the FVIII activity in the blood. Patients with less than 1% activity are classified as severe, those with 1%-5% activity are classified as moderate, and those with more than 5% but less than 40% activity are classified as mild. Severe patients, who account for approximately half of all hemophilia A patients, experience bleeding episodes several times a month, significantly more frequently than moderate and mild patients.

[0005] For bleeding in hemophilia A patients, FVIII preparations are generally administered on demand (on-demand therapy). In recent years, FVIII preparations have also been administered prophylactically to prevent bleeding events (regular replacement therapy; Non-Patent Documents 1 and 2). The half-life of FVIII preparations in the blood is approximately 8 to 19 hours. Therefore, for continuous prevention, FVIII preparations are administered to patients three times a week (Non-Patent Documents 3 and 4). Even in on-demand therapy, FVIII preparations are additionally administered at regular intervals as necessary to prevent recurrence of bleeding. Furthermore, FVIII preparations are mainly administered at home, but because they are administered intravenously, the difficulty of securing blood vessels is a problem. Therefore, there is a strong need for a drug that is less burdensome to administer than FVIII preparations.

[0006] Occasionally, antibodies (inhibitors) against FVIII develop in patients with hemophilia A. Such inhibitors counteract the effects of FVIII preparations. To treat bleeding in patients with inhibitors (inhibitor patients), bypassing agents are administered. The mechanism of action is independent of the function of FVIII, i.e., the function of catalyzing the activation of blood coagulation factor X (FX) by activated blood coagulation factor IX (FIXa). Therefore, in some cases, bypassing agents cannot sufficiently stop bleeding. Recently, results have been obtained that suggest the effectiveness of regular administration of bypassing agents, but the bleeding suppression effect has not been sufficient compared to FVIII preparations. Therefore, there is a strong need for therapeutic agents that can be administered subcutaneously regardless of the presence of inhibitors, and long-acting therapeutic agents that can be administered less frequently.

[0007] Recently, as a means for solving this problem, an antibody emicizumab (ACE910, RO5534262) that substitutes for the function of FVIII and its use have been disclosed (Patent Documents 1, 2, 3, 4, and 5; Non-Patent Documents 5, 6, 7, and 8).

[0008] Emicizumab is a recombinant humanized bispecific antibody that binds (a) FIX and / or FIXa and (b) FX and / or activated blood coagulation factor FX (FXa), mimicking the cofactor function of FVIII. Japanese patients with severe hemophilia A (with or without factor VIII inhibitors) were enrolled in an open-label, nonrandomized, individual-to-individual dose-escalation study of emicizumab. Enrolled patients were assigned to cohort 1, cohort 2, or cohort 3 and received emicizumab subcutaneously at week 0 (day 1) at an initial dose of 1.0 mg per kilogram of body weight (cohort 1) or 3 mg per kilogram (cohorts 2 and 3), followed by subcutaneous doses of 0.3 mg, 1.0 mg, or 3 mg per kilogram (cohorts 1, 2, and 3, respectively) once weekly from week 1 to week 12. The initial and subsequent doses in cohort 3 were identical. Emicizumab reduced annualized bleeding rates (ABR) in patients with hemophilia A with or without factor VIII inhibitors (Non-Patent Document 9). Upon completion of the 12-week study, eligible patients could participate in an extension study (Non-Patent Document 10). [Prior art documents] [Patent documents]

[0009] [Patent Document 1] WO2005 / 035754 [Patent Document 2] WO2005 / 035756 [Patent Document 3] WO2006 / 109592 [Patent Document 4] WO2012 / 067176 [Patent Document 5] WO2015 / 194233 [Non-patent literature]

[0010] [Non-Patent Document 1] Blood 58, 1-13 (1981) [Non-Patent Document 2] Nature 312, 330-337 (1984) [Non-Patent Document 3] Nature 312, 337-342 (1984) [Non-Patent Document 4] Biochim.Biophys.Acta 871, 268-278 (1986) [Non-Patent Document 5] Nature Medicine 18, 1570-1574(2012) [Non-Patent Document 6] PLOS ONE 8, 1-13(2013) [Non-Patent Document 7] J Thromb Haemost. 12, 206-213(2014) [Non-Patent Document 8] Blood 127(13), 1633-1641(2016) [Non-Patent Document 9] N Engl J Med. 374(21), 2044-2053(2016) [Non-Patent Document 10] XXV Congress of the International Society on Thrombosis and Haemostasis, Toronto, Canada, June 20-25, 2015. Abstr AS017. Summary of the Invention

[0011] technical issues The object of the present invention is to provide further effective pharmaceutical compositions or dosing regimens for treating and / or reducing the incidence of diseases whose onset and / or progression is due to a reduction or deficiency in the activity of FVIII and / or activated blood coagulation factor VIII (FVIIIa).

[0012] Solution to the problem As a result of intensive research, the present inventors have succeeded in finding an effective dosing regimen of a pharmaceutical composition containing (a) FIX and / or FIXa and (b) a bispecific antigen-binding molecule (antibody) recognizing FX and / or FXa, for treating and / or reducing the incidence of diseases whose onset and / or progression is due to reduced or deficient activity of FVIII and / or FVIIIa.

[0013] In particular, the present invention relates to pharmaceutical compositions or dosing regimens used to treat and / or reduce the incidence of diseases whose onset and / or progression is due to reduced or deficient activity of FVIII and / or FVIIIa, in particular: [1] A method for treating and / or reducing the incidence of a disease which develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, comprising the steps of: (a) administering to a subject a bispecific antibody that recognizes blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X at a weekly loading dose of 3 mg / kg or 4.5 mg / kg of antibody for one week or more, or at a biweekly loading dose of 6 mg / kg of antibody for two weeks or more; administering one or more maintenance doses of the antibody to the subject after the loading dose is completed, wherein the maintenance dose is 6 mg / kg of antibody; [2] The method of [1], wherein a maintenance dose of 6 mg / kg of the antibody is administered to the subject in one or multiple divided doses every four weeks or every month; [3] The method of [1] or [2], wherein the antibody is administered at a weekly loading dose of 3 mg / kg of antibody for four weeks, followed by a maintenance dose; [4] The method of [1] or [2], wherein the antibody is administered at a weekly loading dose of 4.5 mg / kg of antibody for two weeks, followed by a maintenance dose; [5] The method of [1] or [2], wherein the antibody is administered at a loading dose of 6 mg / kg of antibody every other week for four weeks, followed by a maintenance dose; [6] Any one of methods [1] to [5], in which the maintenance dose is a single dose of 6 mg / kg of antibody administered monthly or every 4 weeks; [7] any one of the methods [1] to [5], wherein the maintenance dose is administered monthly or every four weeks, for two doses of 3 mg / kg of antibody each, wherein one maintenance dose of 3 mg / kg of antibody is administered every two weeks; [8] any one of the methods of [1] to [5], wherein the maintenance dose is administered monthly or every four weeks for four doses of 1.5 mg / kg of antibody each, wherein one maintenance dose of 1.5 mg / kg of antibody is administered once a week; [9] Any one of the methods of [1] to [8], further comprising the step of discontinuing administration of the maintenance dose of the antibody and initiating administration of an alternative maintenance dose of the antibody to the subject in cases where administration of the maintenance dose of the antibody has no or insufficient effect on treating the disease and / or reducing the incidence of the disease, wherein the alternative maintenance dose is a weekly dose of 3 mg / kg of the antibody or a biweekly dose of 6 mg / kg of the antibody;

[10] A method for treating and / or reducing the incidence of a disease which develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, comprising the steps of: (a) administering to a subject a bispecific antibody that recognizes blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X at a weekly loading dose of 4.5 mg / kg of antibody for four weeks; thereafter, administering one or more maintenance doses of the antibody to the subject, the maintenance dose being 9 mg / kg of antibody administered in two or four divided doses every four weeks or every month;

[11] A method for treating and / or reducing the incidence of a disease which develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, comprising the steps of: (a) administering to a subject a bispecific antibody that recognizes blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X at a weekly loading dose of 6 mg / kg of antibody for four weeks; thereafter, administering one or more maintenance doses of the antibody to the subject, the maintenance dose being 12 mg / kg of antibody administered in two or four divided doses every four weeks or every month;

[12] The method of

[10] , further comprising the step of discontinuing administration of the maintenance dose of the antibody and initiating administration of an alternative maintenance dose of the antibody to the subject in cases where administration of the maintenance dose of the antibody has no or insufficient effect on treating the disease and / or reducing the incidence of the disease, wherein the alternative maintenance dose is a weekly dose of 4.5 mg / kg of the antibody;

[13] The method of

[11] , further comprising the step of discontinuing administration of the maintenance dose of the antibody and initiating administration of an alternative maintenance dose of the antibody to the subject in cases where administration of the maintenance dose of the antibody has no or insufficient effect on treating the disease and / or reducing the incidence of the disease, wherein the alternative maintenance dose is a weekly dose of 6 mg / kg of antibody;

[14] The method according to any one of [1] to

[13] , wherein the antibody is emicizumab; and

[15] The method of

[14] , wherein the disease which develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII is selected from the group consisting of hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia A accompanied by the appearance of inhibitors to blood coagulation factor VIII and / or activated blood coagulation factor VIII.

[0014] Furthermore, the present invention relates to:

[16] A pharmaceutical composition comprising (a) a bispecific antibody recognizing blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X for use in treating and / or reducing the incidence of a disease whose onset and / or progression is due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, wherein the bispecific antibody is administered at a weekly loading dose of 3 mg / kg or 4.5 mg / kg of antibody for one or more weeks, or at a biweekly loading dose of 6 mg / kg of antibody for two or more weeks, and after completion of the loading dose administration, one or more maintenance doses of 6 mg / kg of antibody are administered;

[17] A pharmaceutical composition comprising (a) a bispecific antibody recognizing blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X for use in treating and / or reducing the incidence of a disease whose onset and / or progression is due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, wherein the bispecific antibody is administered at a weekly loading dose of 4.5 mg / kg of antibody for 4 weeks, followed by one or more maintenance doses of 9 mg / kg of antibody administered in 2 or 4 divided doses every 4 weeks or every month;

[18] A pharmaceutical composition comprising (a) a bispecific antibody recognizing blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X for use in treating and / or reducing the incidence of a disease which develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, wherein the bispecific antibody is administered at a weekly loading dose of 6 mg / kg of antibody for 4 weeks, followed by one or more maintenance doses of 12 mg / kg of antibody administered in 2 or 4 divided doses every 4 weeks or every month;

[19] An article of manufacture comprising: (i) a container; (ii) a pharmaceutical composition therein comprising a bispecific antibody that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X; and (iii) instructions to administer (a) the bispecific antibody at a weekly loading dose of 3 mg / kg or 4.5 mg / kg of antibody for one week or more, or at a biweekly loading dose of 6 mg / kg of antibody for two weeks or more, and (b) after the loading dose is completed, to administer one or more maintenance doses of the bispecific antibody, wherein the maintenance dose is 6 mg / kg of antibody;

[20] An article of manufacture comprising: (i) a container; (ii) a pharmaceutical composition therein comprising a bispecific antibody that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X; and (iii) instructions to (a) administer the bispecific antibody at a weekly loading dose of 4.5 mg / kg of antibody for four weeks, and (b) administer one or more maintenance doses of the bispecific antibody after the loading dose is completed, wherein the maintenance dose is 9 mg / kg of antibody administered in two or four divided doses every four weeks or monthly;

[21] An article of manufacture comprising: (i) a container; (ii) a pharmaceutical composition therein comprising a bispecific antibody that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X; and (iii) instructions to (a) administer the bispecific antibody at a weekly loading dose of 6 mg / kg of antibody for four weeks, and (b) administer one or more maintenance doses of the bispecific antibody after the loading dose is completed, wherein the maintenance dose is 12 mg / kg of antibody administered in two or four divided doses every four weeks or monthly;

[22] A bispecific antibody recognizing (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X for use in treating and / or reducing the incidence of a disease whose onset and / or progression is due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, the bispecific antibody being administered at a weekly loading dose of 3 mg / kg or 4.5 mg / kg of antibody for at least one week, or at a biweekly loading dose of 6 mg / kg of antibody for at least two weeks, and administered one or more maintenance doses of 6 mg / kg of antibody after completion of the loading dose administration;

[23] A bispecific antibody recognizing (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X for use in treating and / or reducing the incidence of a disease whose onset and / or progression is due to a reduction or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, the bispecific antibody being administered at a weekly loading dose of 4.5 mg / kg of antibody for 4 weeks, followed by one or more maintenance doses of 9 mg / kg of antibody administered in 2 or 4 divided doses every 4 weeks or every month;

[24] A bispecific antibody recognizing (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X for use in treating and / or reducing the incidence of a disease whose onset and / or progression is due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, the bispecific antibody being administered at a weekly loading dose of 6 mg / kg of antibody for 4 weeks, followed by one or more maintenance doses of 12 mg / kg of antibody administered in 2 or 4 divided doses every 4 weeks or every month;

[25] use of a bispecific antibody recognizing (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X in the manufacture of a pharmaceutical composition used to treat and / or reduce the incidence of a disease whose onset and / or progression is due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, wherein the bispecific antibody is administered at a weekly loading dose of 3 mg / kg or 4.5 mg / kg of antibody for one week or more, or at a biweekly loading dose of 6 mg / kg of antibody for two weeks or more, and after completion of the loading dose administration, one or more maintenance doses of 6 mg / kg of antibody are administered;

[26] Use of a bispecific antibody that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X in the manufacture of a pharmaceutical composition used to treat and / or reduce the incidence of a disease whose development and / or progression is due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, wherein the bispecific antibody is administered at a weekly loading dose of 4.5 mg / kg of antibody for 4 weeks, followed by one or more maintenance doses of 9 mg / kg of antibody administered in 2 or 4 divided doses every 4 weeks or every month; and

[27] Use of a bispecific antibody recognizing (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X in the manufacture of a pharmaceutical composition used to treat and / or reduce the incidence of a disease whose start and / or progress is due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIIIa, wherein the bispecific antibody is administered at a weekly loading dose of 6 mg / kg of antibody for 4 weeks, followed by one or more maintenance doses of 12 mg / kg of antibody administered in 2 or 4 divided doses every 4 weeks or every month. [Brief description of the drawings]

[0015] [Figure 1] Figure 1 shows the annualized bleeding rate versus plasma emicizumab concentration determined by simulation. The X-axis shows the plasma emicizumab concentration (μg / mL). The Y-axis shows the cumulative number of bleeding episodes over 52 weeks. The circles and solid lines show the median values ​​determined by simulation plotted at each plasma emicizumab concentration. The shaded area shows the 5th to 95th percentile range determined by simulation. [Diagram 2] Figure 2 shows simulated plasma emicizumab concentrations over time (weekly dosing). The X-axis shows time (weeks) after the first emicizumab dose. The Y-axis shows plasma emicizumab concentrations (μg / mL). The circles and solid lines show simulated median values ​​plotted at each trough sampling time point. The shaded area shows the simulated 5th to 95th percentile range. The dashed line shows the target exposure level of 45 μg / mL. A loading dose of 3 mg / kg was applied once weekly for the first 4 weeks, followed by a maintenance dose of 1.5 mg / kg once weekly. [Diagram 3] Figure 3 shows simulated plasma emicizumab concentrations over time (biweekly dosing). The X-axis shows time (weeks) after the first emicizumab dose. The Y-axis shows plasma emicizumab concentrations (μg / mL). The circles and solid lines show simulated median values ​​plotted at each trough sampling time point. The shaded area shows the simulated 5th to 95th percentile range. The dashed line shows the target exposure level of 45 μg / mL. A loading dose of 3 mg / kg was applied once weekly for the first 4 weeks, followed by a maintenance dose of 3 mg / kg once every 2 weeks. [Figure 4]Figure 4 shows simulated plasma emicizumab concentrations over time (4-week dosing). The X-axis shows time (weeks) after the first emicizumab dose. The Y-axis shows plasma emicizumab concentrations (μg / mL). The circles and solid lines show simulated median values ​​plotted at each trough sampling time point. The shaded area shows the simulated 5-95th percentile range. The dashed line shows the target exposure level of 45 μg / mL. A loading dose of 3 mg / kg was applied once weekly for the first 4 weeks, followed by a maintenance dose of 6 mg / kg once every 4 weeks. [Diagram 5] Figure 5 shows the distribution of annualized bleeding rates determined by simulation (weekly dosing). The X-axis shows the cumulative number of bleeding episodes over 52 weeks. The Y-axis shows the percentage of patients with each cumulative number of bleeding episodes over 52 weeks. The bars show the percentages determined by simulation. A loading dose of 3 mg / kg was applied once weekly for the first 4 weeks, followed by a maintenance dose of 1.5 mg / kg once weekly. [Figure 6] Figure 6 shows the distribution of annualized bleeding rates determined by simulation (biweekly dosing). The X-axis shows the cumulative number of bleeding episodes over 52 weeks. The Y-axis shows the percentage of patients with each cumulative number of bleeding episodes over 52 weeks. The bars show the percentages determined by simulation. A loading dose of 3 mg / kg was applied once weekly for the first 4 weeks, followed by a maintenance dose of 3 mg / kg once every 2 weeks. [Figure 7] Figure 7 shows the distribution of annualized bleeding rates determined by simulation (dosing every 4 weeks). The X-axis shows the cumulative number of bleeding episodes over 52 weeks. The Y-axis shows the percentage of patients with each cumulative number of bleeding episodes over 52 weeks. The bars show the percentages determined by simulation. A loading dose of 3 mg / kg was applied once weekly for the first 4 weeks, followed by a maintenance dose of 6 mg / kg once every 4 weeks. [Figure 8] FIG. 8 shows the annualized bleeding rates for study arms A, B, and C in HAVEN 1 (Example 2). ABR, annualized bleeding rate; BPA, bypassing agent; RR, relative risk. [Figure 9]Figure 9 shows within-participant comparisons of treated bleeds in participants receiving emicizumab prophylaxis (Arm C). Treated bleeds during the period when participants were receiving emicizumab prophylaxis are compared to treated bleeds during the period when the same participants received prior prophylactic BPA therapy within 24 weeks prior to study entry into HAVEN 1. [Figure 10] Figure 10 shows observed trachemicizumab concentrations over time with weekly dosing (3 mg / kg weekly loading dose for the first 4 weeks, followed by 1.5 mg / kg weekly maintenance dose) in HAVEN 1. SD, standard deviation. [Figure 11] Figure 11 shows within-participant comparisons of treated bleeds in participants receiving emicizumab prophylaxis (Arm A). Treated bleeds during the period when participants were receiving emicizumab prophylaxis are compared to treated bleeds during the period when the same participants were receiving prior interbleed BPA treatment within 24 weeks prior to study entry into HAVEN 1. [Figure 12] Figure 12 shows the ABR calculated for individual patients for treated bleeds in HAVEN 2. Within-participant comparisons included patients previously enrolled in NIS who were enrolled in HAVEN 2 for at least 12 weeks. Seven patients received prophylactic treatment with bypassing agents before the study and one received episodic treatment with bypassing agents. ABR, annualized bleeding rate; BPA, bypassing agents; NIS, noninterventional study. [Figure 13] FIG. 13 shows observed and predicted emicizumab concentrations over time with dosing every 4 weeks in the PK run-in part of HAVEN 4 (Example 5). Emicizumab was administered subcutaneously at 6 mg / kg every 4 weeks. Black dots and solid lines indicate individual observations. Grey dashed lines indicate predicted mean values. Thick grey solid lines indicate upper and lower bounds of 95% prediction interval. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Description of the Aspects A bispecific antigen-binding molecule recognizing (a) blood coagulation factor IX (FIX) and / or activated blood coagulation factor IX (FIXa) and (b) blood coagulation factor X (FX) and / or activated blood coagulation factor X (FXa) preferably has an activity substituting for the function of coagulation factor VIII (FVIII).

[0017] In the present invention, the phrase "substitutes for the function of FVIII" means that (a) FIX and / or FIXa and (b) FX and / or FXa are recognized, and activation of FX by FIXa is promoted (FXa production by FIXa is promoted). FXa production promotion activity can be evaluated, for example, using an assay system containing FIXa, FX, synthetic substrate S-2222 (a synthetic substrate for FXa), and phospholipids. Such an assay system shows a correlation between the severity of the disease and clinical symptoms in hemophilia A cases (Rosen S, Andersson M, Blomback M et al. Clinical applications of a chromogenic substrate method for determination of FVIII activity. Thromb Haemost 1985; 54: 811-23).

[0018] Such antigen-binding molecules (such as antibodies) that recognize (a) FIX and / or FIXa and (b) FX and / or FXa can be obtained, for example, according to the methods described in WO2005 / 035756, WO2006 / 109592, and WO2012 / 067176. Specifically, the antibodies can be generated based on the sequences of antibodies against FIX and / or FIXa and antibodies against FX and / or FXa using genetic recombination techniques known to those skilled in the art. Based on the sequences of antibodies against FIX and / or FIXa and antibodies against FX and / or FXa, polynucleotides encoding the antibodies can be constructed and inserted into expression vectors, which can then be expressed in suitable host cells (see, for example, Co, MS et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, AH, Methods Enzymol. (1989) 178, 476-496; Pluckthun, A. and Skerra, A., Methods Enzymol. (1989) 178, 497-515; Lamoyi, E., Methods Enzymol. (1986) 121, 652-663; Rousseaux, J. et al., Methods Enzymol. (1986) 121, 663-669; and Bird, RE and Walker, See BW, Trends Biotechnol. (1991) 9, 132-137).

[0019] In the present invention, the phrases "replace the function of FVIII" and "replace the function of FVIIIa" are used interchangeably.

[0020] Such bispecific antigen-binding molecules can be isolated from inside or outside the host cell (e.g., medium) and purified as substantially pure and homogeneous antibodies. Antibody isolation and purification can be performed using methods commonly used for isolating and purifying antibodies. Methods are not limited to, but can be selected and combined appropriately to isolate and purify antibodies, such as column chromatography columns, filters, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, etc.

[0021] Bispecific antigen-binding molecules of the invention include, for example, the antibodies described in WO2005 / 035756, WO2006 / 109592, and WO2012 / 067176.

[0022] A bispecific antigen-binding molecule comprises a first antigen-binding site and a second antigen-binding site that can specifically bind to at least two different types of antigens. The first antigen-binding site and the second antigen-binding site of the bispecific antigen-binding molecule of the present invention are not particularly limited as long as they have the activity of binding to (a) FIX and / or FIXa and (b) FX and / or FXa, respectively, but examples include sites necessary for binding to antigens, such as antibodies, scaffold molecules (antibody-like molecules), and peptides, as well as fragments containing such sites. A scaffold molecule is a molecule that exhibits function by binding to a target molecule, and any polypeptide can be used as long as it is a conformationally stable polypeptide that can bind to at least one target antigen. Examples of such polypeptides include antibody variable regions, fibronectin (WO2002 / 032925), protein A domain (WO1995 / 001937), LDL receptor A domain (WO2004 / 044011, WO2005 / 040229), ankyrin (WO2002 / 020565), and molecules described in Nygren et al. (Current Opinion in Structural Biology, 7: 463-469 (1997); and Journal of Immunol Methods, 290: 3-28 (2004)), Binz et al. (Nature Biotech 23: 1257-1266 (2005)), and Hosse et al. (Protein Science 15: 14-27 (2006)). Furthermore, peptide molecules capable of binding to target antigens may also be used, as described in Curr Opin Mol Ther. 2010 Aug; 12(4): 487-95 and Drugs. 2008; 68(7): 901-12.

[0023] Bispecific antigen-binding molecules can be produced, for example, using recombinant gene technology (see, for example, Borrebaeck CAK and Larrick JW, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Recombinant antibodies can be obtained by cloning DNA encoding the antibody from an antibody-producing cell, such as a hybridoma or an sensitized lymphocyte that produces the antibody, inserting it into an appropriate vector, and then introducing it into a host (host cell) to produce the antibody.

[0024] Furthermore, the bispecific antigen-binding molecule may be a complete antibody, an antibody fragment, a low molecular weight antibody, or a modified antibody.

[0025] For example, antibody fragments and low molecular weight antibodies include diabodies (Db), linear antibodies, and single chain antibodies (hereinafter also referred to as scFv) molecules. As used herein, the term "Fv" fragment refers to the smallest antibody fragment that contains a complete antigen recognition and binding site.

[0026] Bispecific antibodies include human antibodies, mouse antibodies, rat antibodies, etc., and their origins are not limited. They may be genetically modified antibodies such as chimeric antibodies and humanized antibodies.

[0027] Methods for obtaining human antibodies are known. For example, a human antibody of interest can be obtained by immunizing a transgenic animal carrying a full repertoire of human antibody genes with an antigen of interest (see International Publication Nos. WO93 / 12227, WO92 / 03918, WO94 / 02602, WO94 / 25585, WO96 / 34096, and WO96 / 33735).

[0028] Genetically modified antibodies can also be produced using known methods. Specifically, for example, chimeric antibodies are antibodies that contain the variable regions of the H and L chains of an antibody from an immunized animal and the constant regions of the H and L chains of a human antibody. Chimeric antibodies can be obtained by linking the DNA encoding the variable region of an antibody from an immunized animal to the DNA encoding the constant region of a human antibody, inserting it into an expression vector, and then introducing it into a host cell to produce the antibody.

[0029] Humanized antibody is a modified antibody, often referred to as reshaped human antibody. Humanized antibody is constructed by transferring the CDR of the antibody derived from immunized animal to the complementarity determining region of human antibody. The general gene recombination technology for producing them is also known (see European Patent Application Publication No. EP 239400; International Publication No. WO96 / 02576; Sato K et al., Cancer Research 1993, 53: 851-856; International Publication No. WO99 / 51743).

[0030] More specifically, the bispecific antigen-binding molecule of the present invention is a bispecific antibody in which a first polypeptide is associated with a third polypeptide and a second polypeptide is associated with a fourth polypeptide, and is preferably emicizumab (ACE910, RO5534262) as described below: (a) a bispecific antibody comprising: a first polypeptide which is a heavy chain containing a heavy chain variable region containing the amino acid sequences of CDRs 1, 2, and 3 of SEQ ID NOs:1, 2, and 3, respectively; a second polypeptide which is a heavy chain containing a heavy chain variable region containing the amino acid sequences of CDRs 1, 2, and 3 of SEQ ID NOs:6, 7, and 8, respectively; and third and fourth polypeptides which are shared light chains containing light chain variable regions containing the amino acid sequences of CDRs 1, 2, and 3 of SEQ ID NOs:11, 12, and 13, respectively; (b) a bispecific antibody comprising a first polypeptide, which is a heavy chain containing the heavy chain variable region amino acid sequence of SEQ ID NO:4; a second polypeptide, which is a heavy chain containing the heavy chain variable region amino acid sequence of SEQ ID NO:9; and third and fourth polypeptides, which are a shared light chain containing the light chain variable region amino acid sequence of SEQ ID NO:14; or (c) A bispecific antibody (Q499-z121 / J327-z119 / L404-k), comprising a first polypeptide which is a heavy chain containing the amino acid sequence of SEQ ID NO:5; a second polypeptide which is a heavy chain containing the amino acid sequence of SEQ ID NO:10; and third and fourth polypeptides which are a shared light chain containing the amino acid sequence of SEQ ID NO:15.

[0031] The pharmaceutical compositions of the present invention used for therapeutic or preventive purposes can be prepared by mixing a therapeutic agent, if necessary, with a suitable pharma- ceutically acceptable carrier, medium, etc., and can be made into a lyophilized preparation or a solution preparation.

[0032] As used herein, the term "therapeutic agent" refers to a bispecific antigen-binding molecule of the invention.

[0033] Examples of suitable pharma- ceutically acceptable carriers and vehicles include sterile water, physiological saline, stabilizers, excipients, antioxidants (such as ascorbic acid), buffers (such as phosphate, citric acid, histidine, and other organic acids), preservatives, surfactants (such as PEG and Tween), chelating agents (such as EDTA), and binders. They may contain other low molecular weight polypeptides, proteins such as serum albumin, gelatin, and immunoglobulins, amino acids such as glycine, glutamine, asparagine, glutamic acid, aspartic acid, methionine, arginine, and lysine, sugars and carbohydrates such as polysaccharides and monosaccharides, and sugar alcohols such as mannitol and sorbitol. When preparing an aqueous solution for injection, for example, isotonic solutions containing physiological saline, glucose and other auxiliary agents, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride, can be used, and suitable solubilizers such as alcohol (e.g., ethanol), polyhydric alcohols (such as propylene glycol and PEG), and non-ionic surfactants (such as polysorbate 80, polysorbate 20, poloxamer 188, and HCO-50) can be used in combination. By mixing hyaluronidase in the formulation, a larger liquid volume can be administered subcutaneously (Expert Opin Drug Deliv. 2007 July; 4(4): 427-40). In addition, the pharmaceutical composition of the present invention can be pre-loaded into a syringe. Meanwhile, solution formulations can be prepared according to the method described in WO2011 / 090088.

[0034] If necessary, the antigen-binding molecules of the present invention can be encapsulated in microcapsules (e.g., made of hydroxymethylcellulose, gelatin, and poly(methyl methacrylate)) or prepared as colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) (see, e.g., "Remington's Pharmaceutical Science 16th edition", Oslo Ed. (1980)). Methods for preparing drugs as controlled release drugs are also well known, and such methods can be applied to the antigen-binding molecules of the present invention (Langer et al., J. Biomed. Mater. Res. 15: 267-277 (1981); Langer, Chemtech. 12: 98-105 (1982); U.S. Patent No. 3,773,919; European Patent Application Publication No. EP 58,481; Sidman et al., Biopolymers 22: 547-556 (1983); EP 133,988).

[0035] A preferred liquid formulation is as follows: emicizumab, 20mg / ml to 180mg / ml; Poloxamer 188 at 0.2mg / ml to 1mg / ml, 10mM to 40mM histidine-aspartate buffer, 100 mM to 300 mM arginine (pH of approximately 4.5 to 6.5).

[0036] The pharmaceutical compositions of the present invention may be administered to a patient via any suitable route, for example, intravenously by bolus injection or continuous infusion over a period of time, intramuscularly, intraperitoneally, intracerebrospinally, transdermally, subcutaneously, intraarticularly, sublingually, intrasynovially, orally, by inhalation, topically, or topically. Intravenous or subcutaneous administration is preferred.

[0037] As used herein, the terms "4 weeks" or "monthly" are used interchangeably, and as used herein, the terms "every 4 weeks," "4-weekly," "every month," or "monthly" are used interchangeably.

[0038] As used herein, the terms "every 2 weeks," "2-weekly," or "bi-weekly" are used interchangeably.

[0039] As used herein, a "maintenance" dose refers to one or more doses of a therapeutic agent administered to a patient over a treatment period. Different maintenance doses can be combined with different administration intervals.

[0040] In one aspect, the maintenance dose is 0.3 mg / kg to 24 mg / kg of antibody.

[0041] In one aspect, the administration interval is 1 week to 24 weeks or 6 months.

[0042] In one aspect, the maintenance dose is 6 mg / kg of antibody. A 6 mg / kg maintenance dose refers to, for example, a total of 6 mg / kg of antibody administered in one or multiple divided doses over a four week or monthly period.

[0043] In a particular embodiment, the maintenance dose is 6 mg / kg of antibody, administered once, with a four week (monthly) interval between doses, in which case one dose is administered once a month or every four weeks.

[0044] In another embodiment, the maintenance dose is 6 mg / kg of antibody, administered in two divided doses each containing 3 mg / kg of antibody, with two doses spaced two weeks apart (every two weeks), in this case two doses administered over a one month or four week period.

[0045] In another embodiment, the maintenance dose is 6 mg / kg of antibody, administered in four divided doses each containing 1.5 mg / kg of antibody, with one week (weekly) between doses, in this case four doses administered over a one month or four week period.

[0046] In a particular embodiment, the maintenance dose is 6 mg / kg of antibody as a single dose with a 4 week (monthly) interval between doses, in which case one dose is administered every month or every 4 weeks.

[0047] In another embodiment, the maintenance dose is 3 mg / kg of antibody per dose with a dosing interval of 2 weeks (every 2 weeks), in which case two doses are administered within a 1 month or 4 week period.

[0048] In another embodiment, the maintenance dose is 1.5 mg / kg of antibody per dose with a weekly (every week) interval between doses, in this case four doses over a period of one month or four weeks.

[0049] In another aspect, the maintenance dose is 9mg / kg of antibody. A maintenance dose of 9mg / kg refers to, for example, administering a total of 9mg / kg of antibody in one or multiple doses every 4 weeks or every month. This may be applicable for pediatric patients or such special patient populations where exposure is expected to be lower.

[0050] In a particular embodiment, the maintenance dose is 9 mg / kg of antibody, administered in two divided doses each containing 4.5 mg / kg of antibody, with two doses spaced two weeks apart (every two weeks), in this case one month or four weeks apart.

[0051] In another embodiment, the maintenance dose is 9 mg / kg of antibody, administered in four divided doses each containing 2.25 mg / kg of antibody, with one week (weekly) between doses, in this case four doses administered over a period of one month or four weeks.

[0052] In another specific embodiment, the maintenance dose is 4.5 mg / kg of antibody per dose with a dosing interval of 2 weeks (every 2 weeks), in this case two doses administered within a 1 month or 4 week period.

[0053] In another embodiment, the maintenance dose is 2.25 mg / kg of antibody per dose with a weekly (every week) interval between doses, in this case four doses over a one month or four week period.

[0054] In another aspect, the maintenance dose is 12 mg / kg of antibody. A maintenance dose of 12 mg / kg refers to, for example, administering a total of 12 mg / kg of antibody in one or multiple doses for 4 weeks or every month. This may be applicable for pediatric patients or such special patient populations where exposure is expected to be lower.

[0055] In a particular embodiment, the maintenance dose is 12 mg / kg of antibody, administered in two divided doses each containing 6 mg / kg of antibody, with two doses spaced two weeks apart (every two weeks), in this case two doses administered within a one month or four week period.

[0056] In another embodiment, the maintenance dose is 12 mg / kg of antibody, administered in four divided doses each containing 3 mg / kg of antibody, with one week (weekly) between doses, in this case four doses administered over a period of one month or four weeks.

[0057] In a particular embodiment, the maintenance dose is 6 mg / kg of antibody per dose with a dosing interval of 2 weeks (every 2 weeks), in this case two doses administered within a 1 month or 4 week period.

[0058] In another embodiment, the maintenance dose is 3 mg / kg of antibody per dose with a weekly (every week) interval between doses, in this case four doses over a period of one month or four weeks.

[0059] In other aspects, different or alternative maintenance doses and dosing intervals may be applicable.

[0060] In certain embodiments, different or alternative maintenance doses and dosing intervals may be applicable after the first maintenance dose and dosing interval. More specifically, the above-mentioned 6mg / kg antibody maintenance dosing regimen every 4 weeks, 9mg / kg antibody maintenance dosing regimen every 4 weeks, and / or 12mg / kg antibody maintenance dosing regimen every 4 weeks may be modified to apply different, alternative, or modified maintenance doses and dosing intervals. For example, after administration of any of the above-mentioned 6mg / kg antibody maintenance dosing regimen every 4 weeks, 9mg / kg antibody maintenance dosing regimen every 4 weeks, and 12mg / kg antibody maintenance dosing regimen, administration of the maintenance dose may be evaluated to be sufficient to treat the subject. If administration of the maintenance dose is found to be insufficient or to cause no or insufficient therapeutic and / or prophylactic effect, administration of the maintenance dose of the antibody may be discontinued and administration of the modified maintenance dose may be initiated. The effect of administration of the maintenance dose can be evaluated at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 36 weeks, 48 ​​weeks, 60 weeks, or more after the start of administration of the maintenance dose. The number of times that the maintenance dose can be changed is not particularly limited. The change of the maintenance dose can be performed several times, for example, 1 to 4 times. In other words, one to several, for example one to five, different maintenance doses may be applied successively, such as: (0) administration of a certain maintenance dose, (1) discontinuing administration of that maintenance dose and initiating administration of a first modified maintenance dose, (2) discontinuing administration of the first modified maintenance dose and initiating administration of a second modified maintenance dose, (3) discontinuing administration of the second modified maintenance dose and initiating administration of a third modified maintenance dose, or (4) discontinuing administration of the third modified maintenance dose and initiating administration of a fourth modified maintenance dose.

[0061] In some embodiments, the modified maintenance dose may be applied from the outset without using the aforementioned 6 mg / kg antibody maintenance dosing regimen every 4 weeks, 9 mg / kg antibody maintenance dosing regimen every 4 weeks, and / or 12 mg / kg antibody maintenance dosing regimen.

[0062] In certain aspects, the modified maintenance dose is 6 mg / kg of antibody. A modified maintenance dose of 6 mg / kg refers to, for example, a total of 6 mg / kg of antibody administered in a single dose or in multiple divided doses over a two week period or every two weeks.

[0063] In a particular embodiment, the modified maintenance dose is 6 mg / kg of antibody, which is administered once, and the modified administration interval is 2 weeks (every 2 weeks). In this case, one administration is administered every 2 weeks.

[0064] In another embodiment, the modified maintenance dose is 6 mg / kg of antibody, administered in two divided doses each containing 3 mg / kg of antibody, and the modified dosing interval is one week (every week). In this case, two doses are administered over a two-week period.

[0065] In a particular embodiment, the modified maintenance dose is 6 mg / kg of antibody per dose and the modified dosing interval is 2 weeks (every 2 weeks), in which case 2 doses are administered within a 1 month or 4 week period, or in other words, 1 dose is administered within a 2 week period.

[0066] In another embodiment, the modified maintenance dose is 3 mg / kg of antibody as a single dose and the modified dosing interval is 1 week (every week), in this case two doses administered within a 2 week period.

[0067] In certain embodiments, the modified maintenance dose is 9mg / kg of antibody.A modified maintenance dose of 9mg / kg refers to, for example, administering a total of 9mg / kg of antibody in one or multiple doses for 2 weeks or every 2 weeks.This may be applicable for pediatric patients or such special patient populations that are expected to be exposed to lower doses.

[0068] In another embodiment, the modified maintenance dose is 9 mg / kg of antibody, administered in two divided doses each containing 4.5 mg / kg of antibody, and the modified dosing interval is one week (every week). In this case, two doses are administered over a two-week period.

[0069] In another embodiment, the modified maintenance dose is 4.5 mg / kg of antibody per dose and the modified dosing interval is 1 week (every week), in which case 4 doses are administered over a period of 1 month or 4 weeks, or in other words, 2 doses are administered over a period of 2 weeks.

[0070] In certain embodiments, the modified maintenance dose is 12 mg / kg of antibody. A modified maintenance dose of 12 mg / kg refers to, for example, administering a total of 12 mg / kg of antibody in one or multiple doses for 2 weeks or every 2 weeks. This may be applicable for pediatric patients or such special patient populations where exposure is expected to be lower.

[0071] In another embodiment, the modified maintenance dose is 12 mg / kg of antibody, administered in two divided doses each containing 6 mg / kg of antibody, and the modified dosing interval is one week (every week). In this case, two doses are administered over a two-week period.

[0072] In another embodiment for each divided dose as a modified maintenance dose, the modified maintenance dose is 6 mg / kg of antibody as a single dose and the modified dosing interval is 1 week (every week), in which case 4 doses are administered over a period of 1 month or 4 weeks, or in other words 2 doses are administered over a period of 2 weeks.

[0073] As used herein, a "loading" dose generally includes an initial dose of a therapeutic agent administered to a patient, followed by one or more maintenance doses. In one aspect, a loading dose refers to the amount given in each individual administration, which may be administered 0 to 24 times, preferably at least 1 time, at least 2 times, at least 3 times, at least 4 times, or more, preferably 2 or 4 times. Generally, a loading dose is administered at a treatment interval of 1 to 4 weeks, preferably about every week, about every 2 weeks, about every 3 weeks, or about every 4 weeks (monthly). In one aspect, the loading dose is 0.3 mg / kg to 30 mg / kg, preferably 3 mg / kg, 4.5 mg / kg, or 6 mg / kg of the antibody. The loading dose is intended to achieve steady state therapeutic plasma concentrations as quickly as possible.

[0074] In a particular embodiment, the loading dose is 3 mg / kg, the dosing interval is one week (every week), and the dosing is repeated four times.

[0075] In another embodiment, the loading dose is 4.5 mg / kg, the dosing interval is one week (every week), and the dose is repeated two or four times.

[0076] In another embodiment, the loading dose is 6 mg / kg, the dosing interval is one week (every week), and the dose is repeated four times.

[0077] In another embodiment, the loading dose is 6 mg / kg, the dosing interval is 2 weeks (every 2 weeks), and the dose is repeated twice.

[0078] The number of times that the maintenance dose is administered is not particularly limited, and the number of times can be, for example, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 35, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 500, at least 1000, at least 10,000, or more.

[0079] The "dosing interval" (the interval between individual doses) refers to the interval between the administration of the nth (n is an integer of 1 or more) loading dose and the administration of the (n+1)th loading dose, and the interval between the administration of the nth (n is an integer of 1 or more) maintenance dose and the administration of the (n+1)th maintenance dose.

[0080] In certain embodiments, the antibody is administered as follows. Regimen A: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week). Regimen B: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen C: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 6 mg / kg of antibody administered every 2 weeks. Regimen D: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered every 2 weeks. Regimen E: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered biweekly, followed by a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen F: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, then a maintenance dose of 3 mg / kg of antibody administered every 2 weeks, then a modified maintenance dose of 6 mg / kg of antibody administered every 2 weeks. Regimen G: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered once every 4 weeks (monthly). Regimen H: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered once every 4 weeks (monthly), followed by a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen I: A loading dose of 3 mg / kg of antibody administered weekly for 4 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered once every 4 weeks (monthly), followed by a modified maintenance dose of 6 mg / kg of antibody administered once every 2 weeks. Regimen J: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week). Regimen K: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen L: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 6 mg / kg of antibody administered every 2 weeks. Regimen M: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered every 2 weeks. Regimen N: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered biweekly, followed by a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen O: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, then a maintenance dose of 3 mg / kg of antibody administered every 2 weeks, then a modified maintenance dose of 6 mg / kg of antibody administered every 2 weeks. Regimen P: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered once every 4 weeks (monthly). Regimen Q: A loading dose of 4.5 mg / kg of antibody once a week for 2 weeks, then a maintenance dose of 6 mg / kg of antibody once every 4 weeks (monthly), then a modified maintenance dose of 3 mg / kg of antibody once a week. Regimen R: A loading dose of 4.5 mg / kg of antibody administered weekly for 2 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered once every 4 weeks (monthly), followed by a modified maintenance dose of 6 mg / kg of antibody administered once every 2 weeks. Regimen S: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week). Regimen T: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen U: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 6 mg / kg of antibody administered every 2 weeks. Regimen V: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered every 2 weeks. Regimen W: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, then a maintenance dose of 3 mg / kg of antibody administered every 2 weeks, then a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen X: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered every 2 weeks, followed by a modified maintenance dose of 6 mg / kg of antibody administered every 2 weeks. Regimen Y: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered every 4 weeks (monthly). Regimen Z: A loading dose of 6 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered every 4 weeks (monthly), followed by a modified maintenance dose of 3 mg / kg of antibody administered weekly. Regimen AA: A loading dose of 6 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 6 mg / kg of antibody every 4 weeks (monthly), then a modified maintenance dose of 6 mg / kg of antibody every 2 weeks. Regimen AB: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody once a week (every week). Regimen AC: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen AD: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 4.5 mg / kg of antibody once every 2 weeks. Regimen AE: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, then a maintenance dose of 4.5 mg / kg of antibody once every 2 weeks, then a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen AF: A loading dose of 6 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody once a week (every week). Regimen AG: A loading dose of 6 mg / kg of antibody once a week (every week) for 4 weeks, then a maintenance dose of 3 mg / kg of antibody once a week (every week), then a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen AH: A loading dose of 6 mg / kg of antibody administered weekly (every week) for 4 weeks, followed by a maintenance dose of 6 mg / kg of antibody administered every 2 weeks. Regimen AI: A loading dose of 6 mg / kg of antibody once a week (every week) for 4 weeks, then a maintenance dose of 6 mg / kg of antibody once every 2 weeks, then a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen AJ: A loading dose of 4.5 mg / kg of antibody administered weekly (every week) for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 9 mg / kg of antibody administered every 2 weeks. Regimen AK: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, then a maintenance dose of 4.5 mg / kg of antibody once every 2 weeks, then a modified maintenance dose of 9 mg / kg of antibody once every 2 weeks. Regimen AL: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 9 mg / kg of antibody once every 4 weeks (every month). Regimen AM: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 9 mg / kg of antibody once every 4 weeks (monthly), followed by a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen AN: A loading dose of 4.5 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 9 mg / kg of antibody once every 4 weeks (every month), followed by a modified maintenance dose of 9 mg / kg of antibody once every 2 weeks. Regimen AO: A loading dose of 6.75 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody once a week (every week). Regimen AP: A loading dose of 6.75 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen AQ: A loading dose of 6.75 mg / kg of antibody administered weekly (every week) for 2 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 9 mg / kg of antibody administered every 2 weeks. Regimen AR: A loading dose of 6.75 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 4.5 mg / kg of antibody once every 2 weeks. Regimen AS: A loading dose of 6.75 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 4.5 mg / kg of antibody once every 2 weeks, followed by a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen AT: A loading dose of 6.75 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 4.5 mg / kg of antibody once every 2 weeks, followed by a modified maintenance dose of 9 mg / kg of antibody once every 2 weeks. Regimen AU: A loading dose of 6.75 mg / kg of antibody administered weekly (every week) for 2 weeks, followed by a maintenance dose of 9 mg / kg of antibody administered once every 4 weeks (every month). Regimen AV: A loading dose of 6.75 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 9 mg / kg of antibody once every 4 weeks (every month), followed by a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen AW: A loading dose of 6.75 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 9 mg / kg of antibody once every 4 weeks (every month), followed by a modified maintenance dose of 9 mg / kg of antibody once every 2 weeks. Regimen AX: A loading dose of 9 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week). Regimen AY: A loading dose of 9 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody administered once a week (every week), followed by a modified maintenance dose of 4.5 mg / kg of antibody administered once a week (every week). Regimen AZ: A loading dose of 9 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 9 mg / kg of antibody administered every 2 weeks. Regimen BA: A loading dose of 9 mg / kg of antibody every 2 weeks for 4 weeks, followed by a maintenance dose of 4.5 mg / kg of antibody every 2 weeks. Regimen BB: A loading dose of 9 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 4.5 mg / kg of antibody every 2 weeks, then a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen BC: A loading dose of 9 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 4.5 mg / kg of antibody every 2 weeks, then a modified maintenance dose of 9 mg / kg of antibody every 2 weeks. Regimen BD: A loading dose of 9 mg / kg of antibody every 2 weeks for 4 weeks, followed by a maintenance dose of 9 mg / kg of antibody every 4 weeks (monthly). Regimen BE: A loading dose of 9 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 9 mg / kg of antibody every 4 weeks (monthly), then a modified maintenance dose of 4.5 mg / kg of antibody once a week (weekly). Regimen BF: A loading dose of 9 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 9 mg / kg of antibody administered every 4 weeks (monthly), followed by a modified maintenance dose of 9 mg / kg of antibody administered every 2 weeks. Regimen BG: A loading dose of 6 mg / kg of antibody administered weekly (every week) for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 12 mg / kg of antibody administered every 2 weeks. Regimen BH: A loading dose of 6 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 6 mg / kg of antibody administered every 2 weeks, then a modified maintenance dose of 12 mg / kg of antibody administered every 2 weeks. Regimen BI: A loading dose of 6 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 12 mg / kg of antibody once every 4 weeks (every month). Regimen BJ: A loading dose of 6 mg / kg of antibody once a week (every week) for 4 weeks, then a maintenance dose of 12 mg / kg of antibody once every 4 weeks (monthly), then a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen BK: A loading dose of 6 mg / kg of antibody administered weekly (every week) for 4 weeks, followed by a maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (every month), followed by a modified maintenance dose of 12 mg / kg of antibody administered once every 2 weeks. Regimen BL: A loading dose of 9 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 3 mg / kg of antibody once a week (every week). Regimen BM: A loading dose of 9 mg / kg of antibody once a week (every week) for 2 weeks, then a maintenance dose of 3 mg / kg of antibody once a week (every week), then a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen BN: A loading dose of 9 mg / kg of antibody administered weekly (every week) for 2 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered weekly (every week), followed by a modified maintenance dose of 12 mg / kg of antibody administered every 2 weeks. Regimen BO: A loading dose of 9 mg / kg of antibody given weekly (every week) for 2 weeks, followed by a maintenance dose of 6 mg / kg of antibody given every 2 weeks. Regimen BP: A loading dose of 9 mg / kg of antibody once a week (every week) for 2 weeks, then a maintenance dose of 6 mg / kg of antibody once every 2 weeks, then a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen BQ: A loading dose of 9 mg / kg of antibody once a week (every week) for 2 weeks, then a maintenance dose of 6 mg / kg of antibody once every 2 weeks, then a modified maintenance dose of 12 mg / kg of antibody once every 2 weeks. Regimen BR: A ​​loading dose of 9 mg / kg of antibody administered weekly (every week) for 2 weeks, followed by a maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (every month). Regimen BS: A loading dose of 9 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 12 mg / kg of antibody once every 4 weeks (monthly), followed by a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen BT: A loading dose of 9 mg / kg of antibody once a week (every week) for 2 weeks, followed by a maintenance dose of 12 mg / kg of antibody once every 4 weeks (every month), followed by a modified maintenance dose of 12 mg / kg of antibody once every 2 weeks. Regimen BU: A loading dose of 12 mg / kg of antibody given every 2 weeks for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody given weekly (every week). Regimen BV: A loading dose of 12 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 3 mg / kg of antibody administered once a week (every week), followed by a modified maintenance dose of 6 mg / kg of antibody administered once a week (every week). Regimen BW: A loading dose of 12 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 3 mg / kg of antibody every week, then a modified maintenance dose of 12 mg / kg of antibody every 2 weeks. Regimen BX: A loading dose of 12 mg / kg of antibody given every 2 weeks for 4 weeks, followed by a maintenance dose of 6 mg / kg of antibody given every 2 weeks. Regimen BY: A loading dose of 12 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 6 mg / kg of antibody every 2 weeks, then a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen BZ: A loading dose of 12 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 6 mg / kg of antibody every 2 weeks, then a modified maintenance dose of 12 mg / kg of antibody every 2 weeks. Regimen CA: A loading dose of 12 mg / kg of antibody every 2 weeks for 4 weeks, followed by a maintenance dose of 12 mg / kg of antibody every 4 weeks (monthly). Regimen CB: A loading dose of 12 mg / kg of antibody administered every 2 weeks for 4 weeks, followed by a maintenance dose of 12 mg / kg of antibody administered every 4 weeks (monthly), followed by a modified maintenance dose of 6 mg / kg of antibody administered weekly (weekly). Regimen CC: A loading dose of 12 mg / kg of antibody every 2 weeks for 4 weeks, then a maintenance dose of 12 mg / kg of antibody every 4 weeks (monthly), then a modified maintenance dose of 12 mg / kg of antibody every 2 weeks. Regimen CD: Maintenance dose of 3 mg / kg antibody given once a week (every week). Regimen CE: A maintenance dose of 3 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen CF: A maintenance dose of 3 mg / kg of antibody administered once a week (every week), followed by a modified maintenance dose of 9 mg / kg of antibody administered once every two weeks. Regimen CG: A maintenance dose of 3 mg / kg of antibody administered weekly (every week), followed by a first modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week), followed by a second modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen CH: A maintenance dose of 3 mg / kg of antibody administered weekly (every week), followed by a first modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week), followed by a second modified maintenance dose of 12 mg / kg of antibody administered every two weeks. Regimen CI: A maintenance dose of 3 mg / kg of antibody administered once a week (every week), followed by a first modified maintenance dose of 9 mg / kg of antibody administered once every two weeks, followed by a second modified maintenance dose of 6 mg / kg of antibody administered once a week (every week). Regimen CJ: A maintenance dose of 3 mg / kg of antibody administered once a week (every week), followed by a first modified maintenance dose of 9 mg / kg of antibody administered once every two weeks, followed by a second modified maintenance dose of 12 mg / kg of antibody administered once every two weeks. Regimen CK: A maintenance dose of 3 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen CL: A maintenance dose of 3 mg / kg of antibody administered once a week (every week), followed by a modified maintenance dose of 12 mg / kg of antibody administered once every two weeks. Regimen CM: Maintenance dose of 6 mg / kg antibody given every 2 weeks. Regimen CN: A maintenance dose of 6 mg / kg of antibody administered every 2 weeks, followed by a modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week). Regimen CO: A maintenance dose of 6 mg / kg of antibody given every 2 weeks, followed by a modified maintenance dose of 9 mg / kg of antibody given every 2 weeks. Regimen CP: A maintenance dose of 6 mg / kg of antibody administered once every 2 weeks, followed by a first modified maintenance dose of 4.5 mg / kg of antibody administered once a week (every week), followed by a second modified maintenance dose of 6 mg / kg of antibody administered once a week (every week). Regimen CQ: A maintenance dose of 6 mg / kg of antibody administered every 2 weeks, followed by a first modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week), followed by a second modified maintenance dose of 12 mg / kg of antibody administered every 2 weeks. Regimen CR: A maintenance dose of 6 mg / kg of antibody administered every 2 weeks, followed by a first modified maintenance dose of 9 mg / kg of antibody administered every 2 weeks, followed by a second modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen CS: A maintenance dose of 6 mg / kg of antibody administered every 2 weeks, followed by a first modified maintenance dose of 9 mg / kg of antibody administered every 2 weeks, followed by a second modified maintenance dose of 12 mg / kg of antibody administered every 2 weeks. Regimen CT: A maintenance dose of 6 mg / kg of antibody administered every 2 weeks, followed by a modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen CU: A maintenance dose of 6 mg / kg of antibody given every 2 weeks, followed by a modified maintenance dose of 12 mg / kg of antibody given every 2 weeks. Regimen CV: 12 mg / kg of antibody administered once every 4 weeks (monthly) as a maintenance dose. Regimen CW: A maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (monthly), followed by a modified maintenance dose of 4.5 mg / kg of antibody administered once a week (weekly). Regimen CX: A maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (every month), followed by a modified maintenance dose of 9 mg / kg of antibody administered once every 2 weeks. Regimen CY: A maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (monthly), followed by a first modified maintenance dose of 4.5 mg / kg of antibody administered once a week (weekly), followed by a second modified maintenance dose of 6 mg / kg of antibody administered once a week (weekly). Regimen CZ: A maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (monthly), followed by a first modified maintenance dose of 4.5 mg / kg of antibody administered once a week (weekly), followed by a second modified maintenance dose of 12 mg / kg of antibody administered once every 2 weeks. Regimen DA: A maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (monthly), followed by a first modified maintenance dose of 9 mg / kg of antibody administered once every 2 weeks, followed by a second modified maintenance dose of 6 mg / kg of antibody administered once a week (weekly). Regimen DB: A maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (every month), followed by a first modified maintenance dose of 9 mg / kg of antibody administered once every 2 weeks, followed by a second modified maintenance dose of 12 mg / kg of antibody administered once every 2 weeks. Regimen DC: A maintenance dose of 12 mg / kg of antibody administered once every 4 weeks (monthly), followed by a modified maintenance dose of 6 mg / kg of antibody administered once a week (weekly). Regimen DD: A maintenance dose of 12 mg / kg of antibody every 4 weeks (every month), followed by a modified maintenance dose of 12 mg / kg of antibody every 2 weeks. Regimen DE: Maintenance dose of 4.5 mg / kg antibody given once a week (every week). Regimen DF: A maintenance dose of 4.5 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen DG: A maintenance dose of 4.5 mg / kg of antibody administered once a week (every week), followed by a modified maintenance dose of 12 mg / kg of antibody administered once every two weeks. Regimen DH: Maintenance dose of 9 mg / kg antibody given every 2 weeks. Regimen DI: A maintenance dose of 9 mg / kg of antibody administered every 2 weeks, followed by a modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen DJ: A maintenance dose of 9 mg / kg of antibody given every 2 weeks, followed by a modified maintenance dose of 12 mg / kg of antibody given every 2 weeks. Regimen DK: 6 mg / kg of antibody given once a week (every week) as a maintenance dose. Regimen DL: Maintenance dose of 12 mg / kg antibody given every 2 weeks. Regimen DM: A loading dose of 3 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 1.5 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 2.25 mg / kg of antibody once a week (every week). Regimen DN: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 3 mg / kg of antibody administered weekly (every week). Regimen DO: A loading dose of 3 mg / kg of antibody once a week (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody once a week (every week), then a first modified maintenance dose of 2.25 mg / kg of antibody once a week (every week), then a second modified maintenance dose of 3 mg / kg of antibody once a week (every week), then a third modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen DP: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a third modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week), then a fourth modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen DQ: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a third modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen DR: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week). Regimen DS: A loading dose of 3 mg / kg of antibody once a week (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody once a week (every week), then a first modified maintenance dose of 2.25 mg / kg of antibody once a week (every week), then a second modified maintenance dose of 4.5 mg / kg of antibody once a week (every week), then a third modified maintenance dose of 6 mg / kg of antibody once a week (every week). Regimen DT: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week). Regimen DU: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week), then a third modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen DV: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 1.5 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen DW: A loading dose of 3 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody once a week (every week). Regimen DX: A loading dose of 3 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 3 mg / kg of antibody once a week (every week). Regimen DY: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week). Regimen DZ: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week), then a third modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen EA: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 3 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen EB: A loading dose of 3 mg / kg of antibody once a week (every week) for 4 weeks, followed by a maintenance dose of 2.25 mg / kg of antibody once a week (every week), followed by a modified maintenance dose of 4.5 mg / kg of antibody once a week (every week). Regimen EC: A loading dose of 3 mg / kg of antibody administered weekly (every week) for 4 weeks, then a maintenance dose of 2.25 mg / kg of antibody administered weekly (every week), then a first modified maintenance dose of 4.5 mg / kg of antibody administered weekly (every week), then a second modified maintenance dose of 6 mg / kg of antibody administered weekly (every week). Regimen ED: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 1.5 mg / kg of antibody once a week (weekly), (II-ii) 3 mg / kg of antibody once every 2 weeks, or (II-iii) 6 mg / kg of antibody once every 4 weeks (monthly), followed by a modified maintenance dose of (III) (III-i) 2.25 mg / kg of antibody once a week (weekly), (III-ii) 4.5 mg / kg of antibody once every 2 weeks, or (III-iii) 9 mg / kg of antibody once every 4 weeks (monthly). Regimen EE: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by (II) a maintenance dose of (II-i) 1.5 mg / kg of antibody once a week (weekly), (II-ii) 3 mg / kg of antibody once every 2 weeks, or (II-iii) 6 mg / kg of antibody once every 4 weeks (monthly), followed by (III) administration of a first modified maintenance dose of (III-i) 2.25 mg / kg of antibody once a week (weekly), (III-ii) 4.5 mg / kg of antibody once every two weeks, or (III-iii) 9 mg / kg of antibody once every four weeks (monthly), followed by (IV) administration of a second modified maintenance dose of (IV-i) 3 mg / kg of antibody once a week (weekly), (IV-ii) 6 mg / kg of antibody once every two weeks, or (IV-iii) 12 mg / kg of antibody once every four weeks (monthly). Regimen EF: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 1.5 mg / kg of antibody once a week (weekly), (II-ii) 3 mg / kg of antibody once every 2 weeks, or (II-iii) 6 mg / kg of antibody once every 4 weeks (monthly), followed by a maintenance dose of (III) (III-i) 2.25 mg / kg of antibody once a week (weekly), (I II-ii) a first modified maintenance dose of 4.5 mg / kg of antibody once every 2 weeks, or (III-iii) 9 mg / kg of antibody once every 4 weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 3 mg / kg of antibody once a week (weekly), (IV-ii) 6 mg / kg of antibody once every 2 weeks, or (IV-iii) 12 mg / kg of antibody once every 4 weeks (monthly), followed by (V) a third modified maintenance dose of (Vi) 4.5 mg / kg of antibody once a week (weekly) or (V-ii) 9 mg / kg of antibody once every 2 weeks. Regimen EG: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 1.5 mg / kg of antibody once a week (weekly), (II-ii) 3 mg / kg of antibody once every 2 weeks, or (II-iii) 6 mg / kg of antibody once every 4 weeks (monthly), followed by (III) (III-i) 2.25 mg / kg of antibody once a week (weekly), (III-ii) 4.5 mg / kg of antibody once every 2 weeks, or (III-iii) A first modified maintenance dose of 9 mg / kg of antibody once every 4 weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 3 mg / kg of antibody once a week (weekly), (IV-ii) 6 mg / kg of antibody once every 2 weeks, or (IV-iii) 12 mg / kg of antibody once every 4 weeks (monthly), followed by (V) a third modified maintenance dose of (Vi) 4.5 mg / kg of antibody once a week (weekly) or (V-ii) 9 mg / kg of antibody once every 2 weeks, followed by (VI) a fourth modified maintenance dose of (VI-i) 6 mg / kg of antibody once a week (weekly) or (VI-ii) 12 mg / kg of antibody once every 2 weeks. Regimen EH: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 1.5 mg / kg of antibody once a week (weekly), (II-ii) 3 mg / kg of antibody once every 2 weeks, or (II-iii) 6 mg / kg of antibody once every 4 weeks (monthly), followed by (III) (III-i) 2.25 mg / kg of antibody once a week (weekly), ( III-ii) a first modified maintenance dose of 4.5 mg / kg of antibody once every 2 weeks, or (III-iii) 9 mg / kg of antibody once every 4 weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 3 mg / kg of antibody once a week (weekly), (IV-ii) 6 mg / kg of antibody once every 2 weeks, or (IV-iii) 12 mg / kg of antibody once every 4 weeks (monthly), followed by (V) a third modified maintenance dose of (Vi) 6 mg / kg of antibody once a week (weekly) or (V-ii) 12 mg / kg of antibody once every 2 weeks. Regimen EI: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (every week) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (every week) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by (II) (II-i) 1.5 mg / kg antibody once a week (every week), (II-ii) 3 mg / kg antibody once every 2 weeks, or (II-iii) 6 mg / kg antibody once every 4 weeks (monthly). followed by (III) a first modified maintenance dose of (III-i) 2.25 mg / kg of antibody once a week (weekly), (III-ii) 4.5 mg / kg of antibody once every two weeks, or (III-iii) 9 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 4.5 mg / kg of antibody once a week (weekly) or (IV-ii) 9 mg / kg of antibody once every two weeks. Regimen EJ: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 1.5 mg / kg antibody once a week (weekly), (II-ii) 3 mg / kg antibody once every 2 weeks, or (II-iii) 6 mg / kg antibody once every 4 weeks (monthly), followed by (III) (III-i) 2.25 mg / kg antibody once a week (weekly). g of antibody once a week (weekly), (III-ii) 4.5 mg / kg of antibody once every two weeks, or (III-iii) 9 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 4.5 mg / kg of antibody once a week (weekly) or (IV-ii) 9 mg / kg of antibody once every two weeks, followed by (V) a third modified maintenance dose of (Vi) 6 mg / kg of antibody once a week (weekly) or (V-ii) 12 mg / kg of antibody once every two weeks. Regimen EK: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (every week) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (every week) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by (II) (II-i) 1.5 mg / kg antibody once a week (every week), (II-ii) 3 mg / kg antibody once every 2 weeks, or (II-iii) 6 mg / kg antibody once every 4 weeks (every month). ), followed by (III) a first modified maintenance dose of (III-i) 3 mg / kg of antibody once a week (weekly), (III-ii) 6 mg / kg of antibody once every two weeks, or (III-iii) 12 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 4.5 mg / kg of antibody once a week (weekly) or (IV-ii) 9 mg / kg of antibody once every two weeks. Regimen EL: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 1.5 mg / kg antibody once a week (weekly), (II-ii) 3 mg / kg antibody once every 2 weeks, or (II-iii) 6 mg / kg antibody once every 4 weeks (monthly), followed by a maintenance dose of (III) (III-i) 3 mg / kg (III-ii) 6 mg / kg of antibody once every two weeks, or (III-iii) 12 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 4.5 mg / kg of antibody once every week (weekly) or (IV-ii) 9 mg / kg of antibody once every two weeks, followed by (V) a third modified maintenance dose of (Vi) 6 mg / kg of antibody once every week (weekly) or (V-ii) 12 mg / kg of antibody once every two weeks. Regimen EM: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (every week) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (every week) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by (II) (II-i) 1.5 mg / kg antibody once a week (every week), (II-ii) 3 mg / kg antibody once every 2 weeks, or (II-iii) 6 mg / kg antibody once every 4 weeks (every week). (III) a first modified maintenance dose of (III-i) 3 mg / kg of antibody once a week (weekly), (III-ii) 6 mg / kg of antibody once every two weeks, or (III-iii) 12 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 6 mg / kg of antibody once a week (weekly) or (IV-ii) 12 mg / kg of antibody once every two weeks. Regimen EN: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 2.25 mg / kg of antibody once a week (weekly), (II-ii) 4.5 mg / kg of antibody once every 2 weeks, or (II-iii) 9 mg / kg of antibody once every 4 weeks (monthly). Regimen EO: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 2.25 mg / kg of antibody once a week (weekly), (II-ii) 4.5 mg / kg of antibody once every 2 weeks, or (II-iii) 9 mg / kg of antibody once every 4 weeks (monthly), followed by a modified maintenance dose of (III) (III-i) 3 mg / kg of antibody once a week (weekly), (III-ii) 6 mg / kg of antibody once every 2 weeks, or (III-iii) 12 mg / kg of antibody once every 4 weeks (monthly). Regimen EP: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (every week) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (every week) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by (II) (II-i) 2.25 mg / kg antibody once a week (every week), (II-ii) 4.5 mg / kg antibody once every 2 weeks, or (II-iii) 9 mg / kg antibody once every 4 weeks ( (III) a first modified maintenance dose of (III-i) 3 mg / kg of antibody once a week (weekly), (III-ii) 6 mg / kg of antibody once every two weeks, or (III-iii) 12 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 4.5 mg / kg of antibody once a week (weekly) or (IV-ii) 9 mg / kg of antibody once every two weeks. Regimen EQ: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 2.25 mg / kg antibody once a week (weekly), (II-ii) 4.5 mg / kg antibody once every 2 weeks, or (II-iii) 9 mg / kg antibody once every 4 weeks (monthly), followed by (III) (III-i) 3 mg / kg antibody once a week (weekly). g of antibody once a week (weekly), (III-ii) 6 mg / kg of antibody once every two weeks, or (III-iii) 12 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 4.5 mg / kg of antibody once a week (weekly) or (IV-ii) 9 mg / kg of antibody once every two weeks, followed by (V) a third modified maintenance dose of (Vi) 6 mg / kg of antibody once a week (weekly) or (V-ii) 12 mg / kg of antibody once every two weeks. Regimen ER: (I) a loading dose of (Ii) 3 mg / kg antibody once a week (every week) for 4 weeks, (I-ii) 4.5 mg / kg antibody once a week (every week) for 2 weeks, or (I-iii) 6 mg / kg antibody once every 2 weeks for 4 weeks, followed by (II) (II-i) 2.25 mg / kg antibody once a week (every week), (II-ii) 4.5 mg / kg antibody once every 2 weeks, or (II-iii) 9 mg / kg antibody once every 4 weeks ( (III) a first modified maintenance dose of (III-i) 3 mg / kg of antibody once a week (weekly), (III-ii) 6 mg / kg of antibody once every two weeks, or (III-iii) 12 mg / kg of antibody once every four weeks (monthly), followed by (IV) a second modified maintenance dose of (IV-i) 6 mg / kg of antibody once a week (weekly) or (IV-ii) 12 mg / kg of antibody once every two weeks. Regimen ES: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (weekly) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (weekly) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by a maintenance dose of (II) (II-i) 2.25 mg / kg of antibody once a week (weekly), (II-ii) 4.5 mg / kg of antibody once every 2 weeks, or (II-iii) 9 mg / kg of antibody once every 4 weeks (monthly), followed by a modified maintenance dose of (III) (III-i) 4.5 mg / kg of antibody once a week (weekly) or (III-ii) 9 mg / kg of antibody once every 2 weeks. Regimen ET: (I) a loading dose of (Ii) 3 mg / kg of antibody once a week (every week) for 4 weeks, (I-ii) 4.5 mg / kg of antibody once a week (every week) for 2 weeks, or (I-iii) 6 mg / kg of antibody once every 2 weeks for 4 weeks, followed by (II) (II-i) 2.25 mg / kg of antibody once a week (every week), (II-ii) 4.5 mg / kg of antibody once every 2 weeks, or (II-iii) 9 mg / kg of antibody once a week for 4 weeks. (III) administering a maintenance dose of 4.5 mg / kg of antibody once every four weeks (monthly), followed by (III) administering a first modified maintenance dose of (III-i) 4.5 mg / kg of antibody once every week (weekly) or (III-ii) 9 mg / kg of antibody once every two weeks, followed by (IV) administering a second modified maintenance dose of (IV-i) 6 mg / kg of antibody once every week (weekly) or (IV-ii) 12 mg / kg of antibody once every two weeks.

[0081] In some embodiments, the regimen of the present invention may be applicable for patients suffering from bleeding or excessive bleeding. The regimen of the present invention may be applicable in a method of preventing and / or treating bleeding in such patients, or increasing blood coagulation activity in such patients, or reducing excessive bleeding in such patients. As used herein, "prevention" or "treatment" of bleeding refers to reducing the incidence of bleeding or reducing the likelihood of bleeding in patients. In certain embodiments, excessive bleeding in such patients is caused by reduced or defective activity of FVIII and / or FVIIIa. In certain embodiments, the patient suffering from bleeding has hemophilia, which may be hemophilia A or severe hemophilia A.

[0082] In some embodiments, the regimen of the present invention may be applicable for patients with hemophilia A, preferably for patients with hemophilia A with FVIII inhibitors and / or patients with hemophilia A without FVIII inhibitors.

[0083] In some embodiments, the regimens of the present invention may be applicable for patients with severe hemophilia A.

[0084] In some embodiments, the regimens of the present invention may be applicable for adult patients and / or pediatric patients and / or such special patient populations where exposure is expected to be lower.

[0085] Dosage regimen is determined, for example, by considering efficacy and safety.Furthermore, dosing regimen is determined by considering patient convenience within the range that does not impair efficacy and safety.For example, the dosing regimen for hemophilia A patients can be determined by considering the effect of preventing bleeding in patients and clinically acceptable safety.

[0086] A disorder associated with or caused by bleeding may include a disorder whose onset and / or progression is due to reduced or deficient activity of FVIII and / or FVIIIa.

[0087] Diseases that develop and / or progress due to reduced or deficient activity of FVIII and / or FVIIIa include, but are not limited to, hemophilia A, hemophilia A with the appearance of inhibitors to FVIII / FVIIIa, acquired hemophilia A, and von Willebrand's disease.

[0088] In some embodiments, the regimens of the present invention may be applicable to prevent and reduce the frequency of bleeding episodes in congenital FVIII-deficient patients with inhibitors.

[0089] In some embodiments, the regimens of the present invention may be applicable to prevent and reduce the frequency of bleeding episodes in non-inhibitor congenital FVIII-deficient patients.

[0090] In some embodiments, the regimens of the present invention may be applicable to prevent and reduce the frequency of bleeding episodes in acquired FVIII-deficient patients with inhibitors.

[0091] In some embodiments, the regimens of the present invention may be applicable to prevent and reduce the frequency of bleeding episodes in non-inhibitor acquired FVIII-deficient patients.

[0092] In some embodiments, the regimens of the present invention may be applicable to prevent and reduce the frequency of bleeding episodes in patients with congenital von Willebrand factor deficiency.

[0093] In some embodiments, the regimens of the present invention may be applicable to prevent and reduce the frequency of bleeding episodes in patients with acquired von Willebrand factor deficiency.

[0094] As used herein, the term "inhibitor patient" refers to a patient with hemophilia A who has a FVIII inhibitor.

[0095] As used herein, the term "non-inhibitor patient" refers to a patient with hemophilia A who does not have FVIII inhibitors.

[0096] The present invention provides a product comprising at least (i) a container, (ii) a pharmaceutical composition in said container comprising (a) FIX and / or FIXa and (b) a bispecific antigen-binding molecule that recognizes FX and / or FXa, and (iii) a document instructing administration of the antigen-binding molecule by any of the above-mentioned dosing regimens. In addition, a label, a syringe, a needle, a pharma- ceutical acceptable vehicle, alcohol-soaked cotton, a gauze bandage, etc. may be packaged in the product. The container may be, for example, a bottle, a glass bottle, or a syringe, and may be made of various materials such as glass or plastic. A device to assist administration may be included with the product. The pharmaceutical composition is stored in the container, and the mouth of the container is sealed by a rubber stopper or the like. For example, a label indicating that the pharmaceutical composition is to be used for preventing or treating a selected disease state is attached to the container. The document (iii) may include instructions specifying the loading dose, maintenance dose, frequency or interval of administration according to the above-mentioned dosing regimen.

[0097] Treatment of hemophilia refers to, but is not limited to, stopping bleeding by administering a composition to a hemophilia patient who is actually exhibiting a bleeding episode (treatment of bleeding) and / or reducing the frequency of bleeding by administering a composition to a patient who has previously exhibited bleeding in order to prevent the occurrence of a bleeding episode in advance (prophylaxis of bleeding). Treatment and prevention of bleeding may be understood to have the same meaning in certain cases, and such treatment and prevention of bleeding are also referred to as prophylactic therapy or regular administration therapy of a therapeutic agent (the bispecific antigen-binding molecule of the present invention).

[0098] Prevention of hemophilia refers, for example, to reducing the incidence or likelihood of hemophilia.

[0099] In the present specification, the bleeding events surveyed and counted as the number of bleeding events in a patient are bleeding events that required hemostatic treatment with, for example, coagulation factor preparations. Coagulation factor preparations refer to, for example, FVIII preparations and bypass preparations (activated prothrombin complex preparations, recombinant FVIIa preparations, etc.).

[0100] The number of bleeding episodes per year (annualized bleeding rate (ABR)) is calculated, for example, as (number of bleeding events x 365.25) / number of observation days.

[0101] The present invention provides pharmaceutical compositions comprising (a) FIX and / or FIXa and (b) bispecific antigen binding molecules recognizing FX and / or FXa, or dosing regimens thereof, as more effective pharmaceutical compositions for the prevention and / or treatment of bleeding, bleeding disorders, or disorders caused by bleeding, including those whose onset and / or progression is due to reduced or deficient activity of FVIII and / or FVIIIa.

[0102] All prior art documents cited herein are hereby incorporated by reference. EXAMPLES

[0103] The present invention will be specifically illustrated below with reference to examples, but the present invention should not be construed as being limited thereto.

[0104] Example 1 Effective dosing regimens with extended dosing intervals and / or increased doses Dose-Exposure-Response Model Development A population pharmacokinetic (PopPK) model of emicizumab was developed using quantifiable plasma emicizumab concentration data from 42 healthy subjects (Non-Patent Document 8) and 18 patients with hemophilia A with or without FVIII inhibitors (Non-Patent Documents 9 and 10). Furthermore, bleeding episode data from the same 18 patients (Non-Patent Documents 9 and 10) were used to quantitatively examine the exposure-response relationship for the bleeding prevention efficacy of emicizumab based on a repeated time-to-event (RTTE) modeling approach.

[0105] A one-compartment model with first-order absorption and first-order elimination was used as the structural PopPK model to describe the plasma emicizumab concentration-time profile. Parameter estimates of the PopPK model including covariate effects are listed in Table 1.

[0106] Table 1. Parameter estimates of the population pharmacokinetic model TIFF2024161483000001.tif141132CL / F: Apparent total body clearance, V d / F: apparent volume of distribution, t 1 / 2,abs : primary absorption half-life, ADA: affecting anti-drug antibodies, BW: body weight, PAT: patient. a) Estimated using NONMEM software version 7.2.0 (ICON Development Solutions, Ellicott City, MD, USA), b) Standardized to a typical body weight of 70 kg c) Parameterized as log-transformed geometric mean ratio, d) Parameterized as an allometric exponent (assumed to be in power form),e) Assuming that the exponential error model is followed, f) Assuming that the combined additive + proportional error model is followed, g) Parameterized as the standard deviation, h) Parameterized as the coefficient of variation.

[0107] RTTE modeling addressed bleeding events that occurred both before (i.e., approximately 6 months) and after the initiation of emicizumab treatment, regardless of bleeding site, and that required on-demand use of clotting factor products. The time-varying hazard model, as a structural RTTE model, had a constant baseline hazard (λ) that described the rate of bleeding when treated by on-demand therapy with clotting factor products, and an E that described the bleeding prevention effect of emicizumab as a function of plasma emicizumab concentration. max The model consisted of: The model equation for the RTTE model is illustrated below, and the parameter estimates are listed in Table 2.

[0108]

number

[0109] Table 2. Parameter estimates for the event recurrence interval model TIFF2024161483000003.tif55132λ: Baseline hazard for bleeding events (annualized bleeding rate), EC 50 : Plasma emicizumab concentration required to achieve half the maximum preventive effect on bleeding episodes, E PLX :Effect of ongoing prophylactic therapy with clotting factor products. a)Estimated using NONMEM software version 7.2.0 (ICON Development Solutions, Ellicott City, MD, USA), b) Assumes that the exponential error model is followed.

[0110] Determining Effective Exposure and Justifying Dose Increases The relationship between annualized bleeding rate (ABR) and plasma emicizumab concentration, as determined by simulation with the RTTE model, is shown in Figure 1. A median ABR of 0, indicating freedom from bleeding events for 1 year in 50% or more of patients, is expected to be achieved with a plasma emicizumab concentration of 45 μg / mL or higher.

[0111] With respect to the median ABR, no further improvement in bleeding prevention efficacy outcomes is predicted at plasma emicizumab concentrations of 45 μg / mL or higher. However, due to drug effects and inter-individual variability in baseline ABR, even at such plasma emicizumab concentrations, a significant proportion of patients will remain with an ABR of >0. Therefore, an increase in plasma emicizumab concentration (emicizumab dose) is likely to result in a further reduction in ABR in patients with incomplete bleeding control. Furthermore, in the case of special populations (e.g., pediatric patients) where exposure is expected to be lower, an increase in emicizumab dose would be meaningful to provide an increase in plasma emicizumab concentration and thus a further reduction in ABR.

[0112] Determining Effective Dosage and Justifying Extended Dosing Intervals A loading dose of 3 mg / kg once a week for the first 4 weeks, followed by a maintenance dose of 1.5 mg / kg once a week or a maintenance dose of 3 mg / kg once every 2 weeks was planned to achieve a target exposure level of 45 μg / mL. The loading dose was repeated to achieve a steady-state plasma concentration as soon as possible. The plasma emicizumab concentration-time profiles simulated by the PopPK model for the planned dosing regimens are shown in Figures 2 and 3. The simulations showed that the majority of patients would achieve a target exposure level of 45 μg / mL at steady state (i.e., after 4 weeks) for both dosing regimens.

[0113] Another planned dosing regimen of a loading dose of 3 mg / kg once weekly for the first 4 weeks, followed by a maintenance dose of 6 mg / kg once every 4 weeks, was predicted not to achieve the target exposure level of 45 μg / mL as the median steady-state trough level, while providing higher peak levels with greater peak-trough fluctuations (Figure 4). However, in terms of efficacy, the ABR distributions simulated by the PopPK / RTTE model were predicted to be similar between dosing regimens (Figures 5, 6, and 7). This suggests that a dose given per administration for the maintenance dose higher than the loading dose and extended dosing intervals would provide similar bleeding prevention efficacy to other dosing regimens with a maintenance dose per administration lower or equal to the loading dose.

[0114] Example 2 A randomized, multicenter, open-label, phase III clinical trial evaluating the efficacy, safety, and pharmacokinetics of prophylactic emicizumab compared with no prophylaxis in patients with hemophilia A with inhibitors (HAVEN 1) This multicenter, open-label study evaluated the safety, efficacy, and pharmacokinetics of prophylactic or scheduled emicizumab therapy in patients who had previously received either interim or prophylactic bypassing agent treatment. Interim bypassing agent patients were randomized 2:1 to receive emicizumab prophylaxis (arm A) or no prophylaxis (arm B), and arms A and B were stratified by the number of bleeds (<9 or ≥9) experienced during the last 24 weeks before study entry; arm B patients had the opportunity to switch to emicizumab prophylaxis after 24 weeks on the study. Prophylactic bypassing agent patients switched to emicizumab prophylaxis from the start of the study (arm C); enrollment extended until 24 weeks after the last patient had been enrolled in arms A or B, or until approximately 50 patients had been enrolled in arm C, whichever occurred first. Bleed or prophylactic bypassing agent patients who previously participated in non-interventional study (NIS) BH29768 but were unable to enroll in arms A or B before the cut-off had the opportunity to enroll in arm D until 24 weeks after the last patient enrolled in arms A or B, or until approximately 35 patients had been enrolled in arm D, whichever occurred first. Similar to patients in arms A and C, arm D patients received emicizumab prophylaxis from the start of the study. All patients continued to receive standard of care / background therapy with usual bleed bypassing agent therapy to treat breakthrough bleeds, as needed. - Arm A: Treatment for bleeding + study drug (emicizumab prophylaxis) Patients with inhibitors who had received interbleed treatment with a bypassing agent before study entry (those who met the inclusion criteria for a diagnosis of congenital hemophilia A of any severity and for a documented history of high-titer inhibitors (i.e., ≥5 Bethesda Units ([BU]))) were randomized to receive emicizumab prophylaxis at the start of the trial. - Arm B: Treatment for bleeding (no prophylaxis) Patients with inhibitors who had received interstitial bypassing agent therapy before study entry were randomized to continue interstitial bypassing agent therapy at the start of the study; they had the opportunity to switch to emicizumab prophylaxis after 24 weeks on the study. - Arm C: Study drug (emicizumab prophylaxis) + treatment for bleeding Patients with inhibitors who had received prophylactic treatment with a bypassing agent before study entry received emicizumab prophylaxis at the start of the trial. - Arm D: Study drug (emicizumab prophylaxis) + treatment for bleeding Bleeding or prophylactic bypassing agent patients who previously participated in the noninterventional study BH29768 but were unable to enroll in arms A or B before the cut-off had the opportunity to enroll in arm D receiving emicizumab prophylaxis at the start of the trial.

[0115] Emicizumab was administered subcutaneously at a dose of 3 mg / kg / week for 4 weeks, then 1.5 mg / kg / week until the end of the study.

[0116] The primary endpoint was the reduction in bleeding frequency for patients who received emicizumab subcutaneously at a dose of 3 mg / kg / week for 4 weeks, followed by 1.5 mg / kg / week, compared with patients who did not receive the drug. As described in more detail below, the number of bleeding episodes was significantly reduced in patients who received the drug.

[0117] Study population One hundred and nine participants were enrolled. All participants were male and had a median age of 28 years (range, 12–75 years; Table 3); the median age was lower in arm C, consistent with a higher degree of previous prophylactic BPA use in this younger group. The majority had severe hemophilia, with 7 / 109 participants having mild or moderate disease. Approximately 40% of participants in arms A, B, and D had previously undergone immune tolerance induction (ITI), and 67% of participants in arm C had previously undergone ITI. The majority of participants (69.7%) had a target joint, with 69.7% having >1 target joint. Median (range) emicizumab treatment exposure was 24.0 (3.0–47.9) weeks overall. The median (range) duration of emicizumab treatment exposure was: arm A, 29.5 (3.3-47.9) weeks; arm B, 8.0 (4.0-16.0) weeks; arm C, 19.0 (5.9-45.0) weeks, and arm D, 5.8 (3.0-14.0) weeks.

[0118] Table 3-1. Demographic and baseline characteristics of participants TIFF2024161483000004.tif210170

[0119] (Table 3-2) TIFF2024161483000005.tif77170 * % based on number of participants with target joints; all numbers based on eCRF not NIS data. aPCC, activated prothrombin complex concentrate; NIS, noninterventional study; rFVIIa, recombinant factor VIIa.

[0120] Effectiveness There was a statistically significant and clinically meaningful 87% reduction in bleeding rates between arms A (emicizumab prophylaxis) and B (no prophylaxis); ABR (95% CI) 2.9 (1.69; 5.02) vs. 23.3 (12.33; 43.89), p<0.0001 (Figure 8 and Table 4). Also, statistically significant and clinically meaningful reductions were observed in all secondary bleeding-related endpoints, including spontaneous bleeds, joint bleeds, and target joint bleeds, as well as total bleeds. Overall, 62.9% (22 / 35) of participants randomized to emicizumab prophylaxis experienced 0 bleeds (Figure 8 and Table 4).

[0121] Table 4. Bleeding in study arms TIFF2024161483000006.tif159170 a Negative binomial distribution model. ABR, annualized bleeding rate; BPA, bypassing agent; CI, confidence interval; IQR, interquartile range; RR, relative risk.

[0122] Within-participant comparisons in participants who had previously participated in NIS showed that emicizumab prophylaxis significantly reduced bleeding rates compared with prior BPA prophylaxis (79%: RR 0.21; p=0.0003 [Arm C]); individual participant data are shown in Figure 9 and corresponding data for within-participant comparisons with prior BPA at bleed (Arm A) are shown in Figure 11. Within-participant comparisons of emicizumab prophylaxis with prior BPA at bleed showed a significant reduction in the risk of treated bleeds (92%: RR 0.08; p<0.0001 [Arm A]).

[0123] Emicizumab prophylaxis was associated with statistically significant and clinically meaningful improvements in health-related quality of life (HRQoL) and health status compared with no prophylaxis. Based on adjusted mean differences observed during the study and published literature (Wyrwich et al. Interpreting important health-related quality of life change using the Haem-A-QoL. Haemophilia. 2015; 21(5): 578-584.;Walters and Brazier. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005; 14(6): 1523-1532.;Pickard et al. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007; 5: Clinically important differences determined from the 70.) were as follows: Haem-A-QoL physical health subscale, 21.55 points (p=0.0029) and 10 points; Haem-A-QoL total score, 14.01 points (p=0.0019) and 7 points; EQ-5D-5L VAS, -9.72 points (p=0.0171) and 7 points; and EQ-5D-5L index utility score, -0.16 points (p=0.0014) and 0.07 points, respectively.

[0124] Pharmacokinetic and pharmacodynamic outcomes Mean emicizumab plasma trough concentrations of >50 μg / mL were achieved after 4 weeks with a loading dose of 3 mg / kg / week and were sustained throughout the study with maintenance doses of 1.5 mg / kg / week (Figure 10). D-dimer and prothrombin fragment 1.2 were not affected by emicizumab treatment.

[0125] Example 3 Efficacy, safety, and pharmacokinetics (PK) of weekly prophylactic (Px) emicizumab (ACE910) in children (<12 years) with hemophilia A and inhibitors (PwHAwI): Interim analysis of a single-arm, multicenter, open-label, phase 3 study (HAVEN 2) PwHAwI aged <12 years (or 12–17 years if <40 kg) previously treated with bypassing agents (BPAs) were enrolled in the study to receive emicizumab prophylaxis for at least 52 weeks. Efficacy objectives included annualized bleeding rate (ABR) and reduction in bleeding compared with historical bleeding rate (non-interventional study).

[0126] Participants received weekly subcutaneous (SC) infusions of emicizumab for a designated period of 52 weeks. All participants continued to receive standard of care / background therapy with usual bypassing agents to treat breakthrough bleeding, as needed.

[0127] Emicizumab was administered SC once weekly for 52 weeks, at 3 milligrams per kilogram per week (mg / kg / week) for 4 weeks, then 1.5 mg / kg / week. The regimen was adapted based on efficacy / bleeding control.

[0128] The interim analysis included 20 PwHAwI aged 3-12 (median 8.5) years; 19 aged <12 years were included in the efficacy analysis (Table 5). Median observation time was 12.1 weeks (range 7.1-14.1 weeks). In total, 18 / 19 (94.7%) PwHAwI had 0 treated bleeds and 12 / 19 (63.2%) had no bleeds during the study. Overall, 14 bleeds were reported in 7 PwHAwI; none occurred in joints or muscles. A substantial reduction in ABR during the study compared to ABR from the NIS was observed in 8 PwHAwI included in the within-participant comparison (Figure 12); 8 / 8 had a 100% reduction in the number of treated bleeds, 5 / 8 had a 100% reduction in the number of total bleeds, and all PwHAwI had a >75% reduction in total bleeds. Mean trachemicizumab concentrations of >50 μg / mL were achieved and sustained after 4 weeks.

[0129] Emicizumab Px (prophylaxis) was safe in pediatric PwHAwI, prevented / reduced bleeding, and demonstrated a clinically meaningful reduction in ABR compared to historical ABR. PK was similar to that seen in adult PwHA (persons with hemophilia A). These interim data demonstrate the potential of emicizumab to treat pediatric PwHAwI and reduce disease burden.

[0130] Table 5. Bleeding events in the HAVEN 2 study TIFF2024161483000007.tif23170 a Bleeding / medication questionnaire completed by caregivers via electronic handheld device. Bleeding definition based on ISTH criteria (Blanchette VS, et al. J Thromb Haemost 2014; 12: 1935-39). Treated bleeds: bleeds treated with BPA. All bleeds: bleeds treated with BPA and bleeds not treated. b ABR calculated for participants in the HAVEN 2 study for 12 weeks or more.

[0131] Example 4 A randomized, multicenter, open-label, phase 3 clinical study in participants aged 12 years and older evaluating the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in participants with severe hemophilia A without inhibitors to FVIII (HAVEN 3) This is a randomized, multicenter, open-label, phase 3 clinical study (HAVEN 3) in participants aged 12 years and older to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in participants with severe hemophilia A without inhibitors to FVIII.

[0132] Participants received emicizumab prophylaxis subcutaneously at the prescribed dose until the end of the study (up to 2 years). - Experimental: Emicizumab (pre-study FVIII prophylaxis) Participants who received FVIII prophylaxis before study entry received emicizumab prophylaxis subcutaneously at a dose of 3 mg / kg / week for 4 weeks, followed by emicizumab at 1.5 milligrams per kilogram per week (mg / kg / week) subcutaneously until the end of the study (up to 2 years). - Experimental: emicizumab 1.5mg / kg / week Participants who had received interbleed treatment with FVIII before study entry received emicizumab prophylaxis subcutaneously at a dose of 3 mg / kg / week for 4 weeks, followed by emicizumab subcutaneously at 1.5 mg / kg / week until the end of the study (up to 2 years). - Experimental: emicizumab 3mg / kg / 2 weeks Participants who received interbleed treatment with FVIII before study entry received emicizumab prophylaxis subcutaneously at a dose of 3 mg / kg / week for 4 weeks, followed by emicizumab subcutaneously at 3 mg / kg every 2 weeks (3 mg / kg / 2 weeks) until the end of the study (up to 2 years). - Active comparison: No prophylaxis Participants who received inter-bleed treatment with FVIII before study entry were randomized at the start of the trial to continue inter-bleed FVIII treatment; they had the opportunity to switch to emicizumab prophylaxis after 24 weeks on the study.

[0133] Primary outcome measures: Number of bleeds over time Secondary outcome measures: Reduction in bleeding frequency over time [Time frame: baseline, 24 weeks] Reduction in number of joint bleeds over time [Time frame: baseline, 24 weeks] Reduction in target joint bleeds over time [Time frame: baseline, 24 weeks] Health-Related Quality of Life Score [Time Frame: 24 weeks] Trough plasma concentrations of emicizumab (C trough ) [Time frame: (Before dosing) Every week for weeks 1-4, every 2 weeks for weeks 5-8, every 4 weeks for weeks 9-24, every 8 weeks for weeks 25-48, and every 12 weeks thereafter (for up to 2 years)]

[0134] Example 5 A multicenter, open-label, non-randomized study (HAVEN 4) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg / kg) every 4 weeks in participants with hemophilia A with or without inhibitors to FVIII. This multicenter, open-label, nonrandomized study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg / kg) once every 4 weeks (Q4W) in participants with hemophilia A with or without inhibitors to factor VIII (FVIII). The study consisted of two parts: a pharmacokinetic (PK) run-in part, followed by an expansion part.

[0135] Emicizumab was administered according to the dose and schedule described in each arm. - Experiment: Emicizumab: Extended Part Participants received emicizumab subcutaneously at a loading dose of 3 mg / kg once weekly for the first 4 weeks, followed by a maintenance dose of 6 mg / kg subcutaneously once every 4 weeks for a minimum of 24 weeks. - Experiment: Emicizumab: PK introduction part Participants received emicizumab subcutaneously at a dose of 6 mg / kg once every 4 weeks for a minimum of 24 weeks.

[0136] Primary outcome measures: Extension part: Number of bleeding events over time [Time frame: Extension part: from day 1 to study completion (minimum 24 weeks, up to approximately 20 months)]

[0137] At the data cutoff of April 10, 2017, seven patients with severe hemophilia A (four non-inhibitor and three inhibitor-bearing patients, of whom six patients were aged 18 years or older) were enrolled in the PK run-in cohort and followed for a minimum of 6 weeks. The individual observed PK profiles were within the 95% prediction interval calculated from the population PK model based on clinical data from the 1.5 mg / kg QW regimen (Figure 13: thick grey solid lines indicate the upper and lower limits of the 95% prediction interval). Emicizumab PK parameters obtained after a single SC dose of 6 mg / kg emicizumab (Table 6) were consistent with values ​​observed in a previous study with emicizumab (Uchida et al. Blood 2016; 127(13): 1633-1641). During the observation period (median, 8 weeks), at the time of data cutoff, 14 adverse events (AEs) were reported in 5 patients, including 1 grade 3 serious AE (worsening hypertension); none of the AEs were considered related to the study drug. No anti-drug antibodies were detected. Also, 6 of 7 patients had no bleeding while receiving Q4W emicizumab; 1 patient experienced 3 spontaneous epistaxis episodes on study days 12, 14, and 21, which did not require treatment.

[0138] Table 6. Summary of PK parameters following a single SC dose of 6 mg / kg emicizumab TIFF2024161483000008.tif28170 * T max Median (range) for and geometric mean (CV%) for all other parameters.

[0139] Preliminary data from the HAVEN 4 study demonstrated that Q4W dosing of emicizumab at 6 mg / kg per dose demonstrated PK behavior consistent with historical expectations and resulted in expected steady-state mean concentrations similar to clinically validated dosing regimens (i.e., 1.5 mg / kg / QW). Safety and efficacy results from this PK induction cohort enabled initiation of the HAVEN 4 expansion cohort and provided promising support for the Q4W emicizumab prophylaxis regimen for the management of hemophilia A. The HAVEN 4 study is fully enrolled (N=48, including PK induction cohort patients).

[0140] Example 6 A multicenter, open-label, phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of subcutaneous emicizumab in pediatric patients with hemophilia A and inhibitors The study protocol of HAVEN 2 (see Example 3) was amended to evaluate two additional emicizumab dosing schedules (every 2 weeks [Q2W] and every 4 weeks [Q4W]) as well as the originally planned dosing schedule (every week [QW]).

[0141] Overall, this non-randomized, multicenter, open-label, Phase III clinical study will enroll children with hemophilia A and inhibitors to FVIII. Children with hemophilia A and a documented history of FVIII inhibitor titers (≥5BU) must be currently receiving treatment with a bypassing agent. The study will enroll approximately 80 patients, with an allowance for at least 40 patients under 12 years of age and patients aged 12-17 years who weigh <40 kg at the time of informed consent.

[0142] Patients enrolled in cohort A will receive emicizumab at a loading dose of 3 mg / kg per dose once weekly (QW) for the first 4 weeks, followed by a maintenance dose of 1.5 mg / kg per dose QW for a total of a minimum of 52 weeks. Patients enrolled in cohorts B and C will receive emicizumab at an identical loading dose of 3 mg / kg QW for the first 4 weeks, followed by a maintenance dose of 3 mg / kg Q2W (cohort B) or 6 mg / kg Q4W (cohort C) for a total of a minimum of 52 weeks. During the 52-week treatment period, individual patients may have their dose increased if they are experiencing suboptimal bleeding control with emicizumab.

[0143] Efficacy analyses will evaluate the clinical effect of prophylactic emicizumab on the number of bleeds over time (i.e., bleed rate) and explore the efficacy of dose escalation at the intrapatient level. Bleeds with different bleed definitions, such as treated bleeds, total bleeds, treated spontaneous bleeds, treated joint bleeds, and treated targeted joint bleeds, will be analyzed separately. The primary analysis will be performed 52 weeks after the last patient is enrolled in the primary cohort or early discontinuation, whichever occurs first, where the primary cohort consists of all patients enrolled in Cohort A before the enrollment cut-off for patients aged 2 years or older. No formal hypothesis testing is planned in this study.

[0144] Results from an interim analysis in Cohort A are presented in Example 3.

[0145] Example 7 A multicenter, open-label, phase 3 clinical study evaluating the efficacy, safety, and pharmacokinetics of emicizumab administered every 2 weeks or every 4 weeks in pediatric patients aged 12 years or younger with hemophilia A without factor VIII inhibitors This is a multicenter, open-label, randomized study evaluating the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously at a dose of 3 mg / kg per dose once every 2 weeks (Q2W cohort) or at a dose of 6 mg / kg per dose once every 4 weeks (Q4W cohort) in pediatric patients with hemophilia A without inhibitors. The study will enroll a minimum of 6 patients in each cohort who are less than 12 years of age with hemophilia A without inhibitors.

[0146] The Q2W cohort of this study will receive a loading dose of emicizumab of 3 mg / kg administered subcutaneously once weekly (QW) for the first four doses, followed by a maintenance dose of 3 mg / kg administered subcutaneously every two weeks (Q2W) for a total of at least 24 weeks. The Q4W cohort will receive a loading dose of emicizumab of 3 mg / kg administered subcutaneously once weekly (QW) for the first four doses, followed by a maintenance dose of 6 mg / kg administered subcutaneously every four weeks (Q4W) for a total of at least 24 weeks. For patients who meet the inadequate bleeding control criteria after week 12 of emicizumab treatment, a higher dose may be selected.

[0147] Efficacy analyses will evaluate the clinical effect of emicizumab prophylaxis based on bleeding frequency (bleeding rate) over a defined period. Bleeding with various different definitions, such as bleeding requiring the use of clotting factors for hemostasis, spontaneous bleeds, joint bleeds, target joint bleeds, and total bleeds, will be analyzed separately. Primary efficacy analyses will be performed in each cohort when all patients have completed 24 weeks of treatment or discontinued from the study, whichever occurs first. No statistical hypothesis testing is planned.

Claims

[Claim 1] The invention described in the specification.

Citation Information

Patent Citations

  • Double specific antibodies substituting for functional protein

    WO2005035754A1

  • Bispecific antibody substituting for functional proteins

    WO2005035756A1

  • Antibody substituting for function of blood coagulation factor viii

    WO2006109592A1

  • Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii

    WO2012067176A1

  • Pharmaceutical composition for use in prevention and / or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and / or activated blood coagulation factor viii

    WO2015194233A1

Cited By

  • Screw compressor and refrigeration device

    EP4782693A1

  • Screw compressor and refrigeration device

    WO2026063135A1